MedTrace Logo

Impact of Treatment With VENARUS® on the Level of Monocyte Chemoattractant Protein 1 in Varicose Veins Blood

NCT04933591 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-03-31

No results posted yet for this study

Summary

This study is designed to find if the venoactive drug contained diosmin and hesperidin is able to work against chronic vein-specific inflammation by changing the level of Monocyte Chemoattractant Protein 1. This chemokine is involved in the vein wall remodeling in patients with lower limb varicose veins.

Conditions

  • Varicose Veins

Interventions

DRUG

Diosmin / Hesperidin

Venoactive drugs are used for patients with varicose veins as a tool for alleviating symptoms

Sponsors & Collaborators

  • Pirogov Russian National Research Medical University

    lead OTHER

Principal Investigators

  • Igor Zolotukhin, PhD · Pirogov Russian National Research Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-08-28
Completion
2021-09-28

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04933591 on ClinicalTrials.gov